Case number# PHEH2015US006536, is an initially report received from a consumer via a patient oriented program 
((b) (6)  POP00002028) on 01 Apr 2015. This report refers to a 04-year-old male patient. Medical history 
was not reported. Concomitant medications included Acetaminophen (paracetamol), ibuprofen, Trileptal 
(oxcarbazepine) and vitamin supplements with omega 3, Claritin (loratadine) and Onfi (clobazam). The patient 
received Afinitor (everolimus) orally for the treatment of tuberous sclerosis, brain and spinal cord frontal 
ganglioglioma from 13 Jan 2014 at a dose of 6 mg, QD. The patient had ear tubes placed and had his adenoids 
removed (adenoidectomy) on 20 Dec 2014. In Feb 2015, the patient developed pneumonia. On (b) (6)  the 
patient had viral lung infection (viral infection) (lung infection). The patient went to urgent care center on the same 
day ((b) (6) ). The patient was prescribed levalbuterol inhalation (INH). On an unknown date, the patient 
received Motrin (ibuprofen) and Tylenol (paracetamol) for symptom relief. Therapy status with Afinitor was 
unknown. The patient fully recovered from pneumonia on an unknown date. The outcome of the other events was 
Print Time: 15-JUL-2016 02:35 PM If a field is blank, there is no data for that field Page 99 of 517
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
reported as condition unchanged. The events pneumonia, viral infection and lung infection was assessed as non 
serious event by the reporter. The causality of the event pneumonia was suspected and for other events not 
reported. The seriousness assessment of the event (pneumonia) was upgraded on the basis of available 
information in the source documents. No consent was given to contact with HCP.
Follow up report received from a consumer on 20 Oct 2015: Added concomitants, treatments and new events (viral 
infection and lung infection) and the outcome, seriousness and causality of the events were updated.
Follow up report received from a consumer (patient mother) on 27 Jan 2016: Updated (dose regimen) and causality
of event pneumonia.